| HOME >> BIOLOGY >> TECHNOLOGY |
Nine Months Ended
September 30, 2011
2010
2011
2010 Revenues:Sponsored research and development$ 2,396
$ 5,210
$ 8,589
$ 6,519Milestones and license fees39,238
9,238
57,714
13,325Total revenues41,634
14,448
66,303
19,844Operating expenses:Research and development7,456
8,227
22,949
23,086General and administrative3,825
3,635
9,790
9,950Cease-use expense(87)
120
89
401Total operating expenses11,194
11,982
32,828
33,437Income (loss) from operations30,440
2,466
33,475
(13,593)Other income:Gain on sale/disposal of assets86
34
184
202Deferred gain on real estate736
715
2,209
2,145Investment income, net102
118
341
732Other income, net18
—
31
59Total other income942
867
2,765
3,138Net income (loss)$ 31,382
$ 3,333
$ 36,240
$ (10,455)Net income (loss) per common share:Basic$ 0.57
$ 0.06<
'/>"/>SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved
Related biology technology :
1. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
2. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
6. Neurocrine Biosciences Reports Third Quarter 2008 Results
7. Neurocrine Biosciences to Present at the 20th Annual Piper Jaffray Health Care Conference
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2008 Financial Results
9. Neurocrine Biosciences to Present at the Cowen and Company 29th Annual Health Care Conference
10. Neurocrine Biosciences to Present at the 16th Annual Future Leaders in the Biotech Industry Conference
11. Neurocrine Announces Work Force Restructuring